Susquehanna International Group
ENTA icon

Susquehanna International Group’s Enanta Pharmaceuticals ENTA Stock Holding History

Susquehanna International Group’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$280K Sell
22,200
-77,200
-78% -$1.03M ﹤0.01% 11023
2025
Q4 		$1.57M Buy
99,400
+71,200
+252% +$904K ﹤0.01% 6140
2025
Q3 		$338K Buy
+28,200
New +$225K ﹤0.01% 9842
2023
Q2 		– Sell
-45,300
Closed -$1.83M – 12324
2023
Q1 		$1.83M Sell
45,300
-20,300
-31% -$969K ﹤0.01% 5327
2022
Q4 		$3.05M Sell
65,600
-6,500
-9% -$296K ﹤0.01% 3993
2022
Q3 		$3.74M Buy
72,100
+32,000
+80% +$1.87M ﹤0.01% 3651
2022
Q2 		$1.9M Buy
40,100
+16,200
+68% +$879K ﹤0.01% 5020
2022
Q1 		$1.7M Sell
23,900
-100
-0.4% -$6.51K ﹤0.01% 5837
2021
Q4 		$1.79M Buy
24,000
+6,700
+39% +$526K ﹤0.01% 5762
2021
Q3 		$983K Buy
+17,300
New +$855K ﹤0.01% 7594
2021
Q2 		– Sell
-8,900
Closed -$439K – 12715
2021
Q1 		$439K Buy
+8,900
New +$444K ﹤0.01% 9776
2020
Q1 		– Sell
-48,600
Closed -$3M – 10381
2019
Q4 		$3M Sell
48,600
-5,400
-10% -$335K ﹤0.01% 3698
2019
Q3 		$3.24M Buy
54,000
+26,100
+94% +$1.94M ﹤0.01% 3364
2019
Q2 		$2.35M Buy
27,900
+16,000
+134% +$1.44M ﹤0.01% 3868
2019
Q1 		$1.14M Sell
11,900
-35,700
-75% -$3.2M ﹤0.01% 4800
2018
Q4 		$3.37M Sell
47,600
-300
-0.6% -$23K ﹤0.01% 2770
2018
Q3 		$4.09M Buy
47,900
+7,200
+18% +$721K ﹤0.01% 2923
2018
Q2 		$4.72M Buy
40,700
+14,500
+55% +$1.45M ﹤0.01% 2782
2018
Q1 		$2.12M Buy
26,200
+16,100
+159% +$1.24M ﹤0.01% 3804
2017
Q4 		$593K Sell
10,100
-9,100
-47% -$456K ﹤0.01% 6314
2017
Q3 		$899K Sell
19,200
-5,900
-24% -$237K ﹤0.01% 5465
2017
Q2 		$903K Buy
25,100
+11,900
+90% +$381K ﹤0.01% 5473
2017
Q1 		$407K Sell
13,200
-1,300
-9% -$40.5K ﹤0.01% 6860
2016
Q4 		$486K Sell
14,500
-6,300
-30% -$181K ﹤0.01% 7052
2016
Q3 		$553K Sell
20,800
-10,300
-33% -$239K ﹤0.01% 5885
2016
Q2 		$686K Sell
31,100
-8,300
-21% -$217K ﹤0.01% 5562
2016
Q1 		$1.16M Buy
39,400
+8,600
+28% +$239K ﹤0.01% 4788
2015
Q4 		$1.02M Buy
30,800
+12,700
+70% +$414K ﹤0.01% 5367
2015
Q3 		$654K Sell
18,100
-16,100
-47% -$691K ﹤0.01% 6599
2015
Q2 		$1.54M Buy
34,200
+20,200
+144% +$786K ﹤0.01% 5269
2015
Q1 		$429K Sell
14,000
-5,100
-27% -$198K ﹤0.01% 7365
2014
Q4 		$971K Buy
19,100
+4,600
+32% +$206K ﹤0.01% 5934
2014
Q3 		$574K Sell
14,500
-6,600
-31% -$263K ﹤0.01% 6959
2014
Q2 		$909K Buy
+21,100
New +$805K ﹤0.01% 6249

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Susquehanna International Group's ENTA Position: Q1 2026 in Review

Susquehanna International Group increased its Enanta Pharmaceuticals (ENTA) stake by 36% in Q1 2026, buying an estimated $50.1K and bringing the position to 14,208 shares worth $179K. The position accounts for ﹤0.01% of the portfolio, ranked #11807.

Susquehanna International Group first reported a position in ENTA in Q1 2014 and has held it in 36 quarters since. The position peaked at $5.62M in Q2 2019. 133 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Susquehanna International Group held 14,208 shares of Enanta Pharmaceuticals worth $179K as of Q1 2026.
  • Susquehanna International Group bought 3,741 Enanta Pharmaceuticals shares in Q1 2026, an estimated $50.1K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11807 holding.
  • Susquehanna International Group first reported a position in Enanta Pharmaceuticals in Q1 2014 and has held it in 36 quarters since.
  • Susquehanna International Group's Enanta Pharmaceuticals position peaked at $5.62M in Q2 2019.
  • 133 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.